Will This Billion-Dollar Acquisition Be a Smart Move for Merck?

Will This Billion-Dollar Acquisition Be a Smart Move for Merck?

Because new medicines come with patent protection for lengthy periods of time, the pharmaceutical industry is unsurprisingly a very lucrative one. Few companies do these two things better than Merck (NYSE: MRK). Earlier this month the pharmaceutical giant closed its $1.35 billion, all-cash deal with the oncology company Imago BioSciences.